Krystal leverages its proprietary platform to develop novel, redosable gene therapies for diseases with a high unmet medical need.
Krystal Pipeline
Near-term focus on three target tissues with additional pipeline expansion under investigation.
![pipeline-krystal Krystal Biotech Pipeline](https://www.krystalbio.com/wp-content/uploads/2023/10/pipeline-image-new-2.jpg)
Jeune Aesthetics Pipeline
Jeune Aesthetics, a wholly-owned subsidiary of Krystal Biotech, uses the same platform to treat aesthetic skin conditions.
![jeune](https://www.krystalbio.com/wp-content/uploads/2023/11/jeune2-removebg-preview.png)
Not an actual patient
![Jeune Logo](https://www.krystalbio.com/wp-content/uploads/2023/11/Asset-23.png)
Get more information on Jeune Aesthetics, Inc.
Discovering, developing, and commercializing genetic medicines with purpose